Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
7
Bullish
2
Bearish
13
Neutral
7
Bullish
26
Bearish
8
Neutral
0
Bullish
24
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions.
The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases.
Eris has materially improved insulin market positions since the Biocon acquisition: RHI cartridge share tripled (10% Apr‑24 to 28% Dec‑25) and overall RHI+Glargine share rose from 9% to 16%, underpinning a stated objective of 25% market share and in‑house insulin manufacturing ramp at Bhopal.
International business is transitioning to a CDMO‑led growth engine, reporting Q3 revenue Rs.111 crore (+45% YoY) and providing FY27 international visibility of Rs.550–600 crore revenue with EBITDA Rs.180–200 crore, reflecting confirmed contracts, CDMO investments, and planned export scale from AMD and Biologics sites.
Balance sheet and capital allocation: net debt reduced materially from ~4x to ~2x Net Debt/TTM EBITDA, with a targeted <1.5x by Dec‑26 while maintaining Rs.750–800 crore capex guidance for FY26–FY28 to support injectables, insulin/GLP‑1 and CDMO expansion.
Pharmaceuticals & Biotechnology
Pharmaceuticals
19,212 Cr
Low Risk
44.5
34.2
1.0
5.5
1,909.55
1,237.90
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
ERIS Lifesciences Ltd (ERIS) is currently trading at 1,394.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Eris Lifesciences is an Indian branded formulations company focused on chronic and specialist therapies with expanding sterile injectables and biologics capabilities; it develops, manufactures and commercializes products across cardiology, diabetes, dermatology and other specialty areas and now owns EU‑GMP capable biologics and sterile injectable assets after multiple strategic acquisitions. The Domestic Branded Formulations (DBF) segment delivered steady growth (Q3 DBF revenue Rs.696 crore, +10% YoY) with strong profitability (Q3 DBF EBITDA margin ~36.5% and 9M margin ~37.1%), and management expects FY26 DBF growth of ~12% and Q4 to reflect the full benefit of recent price increases. Eris has materially improved insulin market positions since the Biocon acquisition: RHI cartridge share tripled (10% Apr‑24 to 28% Dec‑25) and overall RHI+Glargine share rose from 9% to 16%, underpinning a stated objective of 25% market share and in‑house insulin manufacturing ramp at Bhopal. International business is transitioning to a CDMO‑led growth engine, reporting Q3 revenue Rs.111 crore (+45% YoY) and providing FY27 international visibility of Rs.550–600 crore revenue with EBITDA Rs.180–200 crore, reflecting confirmed contracts, CDMO investments, and planned export scale from AMD and Biologics sites. Balance sheet and capital allocation: net debt reduced materially from ~4x to ~2x Net Debt/TTM EBITDA, with a targeted <1.5x by Dec‑26 while maintaining Rs.750–800 crore capex guidance for FY26–FY28 to support injectables, insulin/GLP‑1 and CDMO expansion.
Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,237.90 and a high of ₹1,909.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
ERIS Lifesciences Ltd has a market capitalization of approximately 19,212.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
ERIS Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 44.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 19,212.44 Cr, ERIS Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
ERIS Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 44.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Semaglutide is the active pharmaceutical ingredient in drugs like Ozempic, used to treat type-2 diabetes. This launch is significant because it introduces generic versions in India at a fraction of the original's cost, making it accessible to many more patients.
The 'Biopharma Shakti' initiative, with a 10,000 crore rupee outlay, directly supports domestic production of biologics and biosimilars, R&D, and clinical trials. This benefits Eris Lifesciences by fostering innovation, providing access to skilled talent, and streamlining regulatory processes for new product development.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4859.30 | 22,009 Cr | 25.79 | 5.72 | 3.43 | 18.36 | 24.12 | 18.53 | ||
7800.00 | 21,223 Cr | 105.65 | 26.56 | 0.38 | 28.93 | 37.48 | 12.44 | ||
1752.30 | 21,048 Cr | 1047.16 | 3.56 | 0.00 | 2.34 | 3.64 | 0.25 | ||
1027.85 | 21,028 Cr | 13.50 | 2.43 | 0.51 | 17.79 | 21.15 | 14.81 | ||
1344.50 | 19,212 Cr | 44.50 | 5.47 | 0.52 | 13.45 | 14.38 | 6.57 | ||
485.80 | 18,681 Cr | 66.69 | 4.93 | 0.00 | 10.47 | 11.28 | 4.65 | ||
711.85 | 18,644 Cr | 31.33 | 3.67 | 0.23 | 11.70 | 13.63 | 7.71 | ||
| Median: 7 Co. | — | 1344.50 | 21,028 Cr | 44.50 | 4.93 | 0.38 | 13.45 | 14.38 | 7.71 |
